全文获取类型
收费全文 | 2794篇 |
免费 | 161篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 36篇 |
妇产科学 | 30篇 |
基础医学 | 369篇 |
口腔科学 | 71篇 |
临床医学 | 236篇 |
内科学 | 480篇 |
皮肤病学 | 36篇 |
神经病学 | 189篇 |
特种医学 | 471篇 |
外科学 | 633篇 |
综合类 | 7篇 |
预防医学 | 57篇 |
眼科学 | 43篇 |
药学 | 95篇 |
中国医学 | 1篇 |
肿瘤学 | 209篇 |
出版年
2023年 | 56篇 |
2022年 | 39篇 |
2021年 | 147篇 |
2020年 | 80篇 |
2019年 | 103篇 |
2018年 | 139篇 |
2017年 | 101篇 |
2016年 | 122篇 |
2015年 | 116篇 |
2014年 | 143篇 |
2013年 | 165篇 |
2012年 | 257篇 |
2011年 | 237篇 |
2010年 | 128篇 |
2009年 | 106篇 |
2008年 | 160篇 |
2007年 | 165篇 |
2006年 | 123篇 |
2005年 | 100篇 |
2004年 | 76篇 |
2003年 | 72篇 |
2002年 | 93篇 |
2001年 | 17篇 |
2000年 | 10篇 |
1999年 | 9篇 |
1998年 | 12篇 |
1997年 | 6篇 |
1996年 | 7篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1988年 | 4篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1980年 | 6篇 |
1977年 | 5篇 |
1968年 | 4篇 |
1931年 | 5篇 |
1928年 | 6篇 |
1927年 | 4篇 |
1923年 | 4篇 |
1910年 | 3篇 |
1907年 | 3篇 |
1905年 | 3篇 |
1902年 | 3篇 |
1896年 | 3篇 |
1893年 | 5篇 |
排序方式: 共有2974条查询结果,搜索用时 31 毫秒
1.
von Heesen Maximilian Schuld Jochen Hollnder Sebastian Spiliotis Antonios E. Merscher Anna Scherber Philipp R. Igna Dorian Gbelein Gereon Glanemann Matthias 《European Surgery》2022,54(6):317-325
European Surgery - The beneficial outcomes of hepatectomy in patients with colorectal metastases have encouraged the attempts of repeated hepatectomy in patients with recurrent disease. Although... 相似文献
2.
3.
4.
Martin Liebl Federico Pedersoli Markus Zimmermann Maximilian Schulze-Hagen Daniel Truhn Paul Sieben Saskia von Stillfried Anna Tschinaev Alexander Heinzel Christiane K. Kuhl Philipp Bruners Peter Isfort 《Journal of vascular and interventional radiology : JVIR》2021,32(6):836-842.e2
PurposeTo compare hepatic hypertrophy in the contralateral lobe achieved by unilobar transarterial radioembolization (TARE) versus portal vein embolization (PVE) in a swine model.MethodsAfter an escalation study to determine the optimum dose to achieve hypertrophy after unilobar TARE in 4 animals, 16 pigs were treated by TARE (yttrium-90 resin microspheres) or PVE (lipiodol/n-butyl cyanoacrylate). Liver volume was calculated based on CT before treatment and during 6 months of follow-up. Independent t-test (P < .05) was used to compare hypertrophy. The relationship between hypertrophy after TARE and absorbed dose was calculated using the Pearson correlation.ResultsAt 2 and 4 weeks after treatment, a significantly higher degree of future liver remnant hypertrophy was observed in the PVE group versus the TARE group, with a median volume gain of 31% (interquartile range [IQR]: 16%–66%) for PVE versus 23% (IQR: 6%–36%) for TARE after 2 weeks and 51% (IQR: 47%–69%) for PVE versus 29% (IQR: 20%–50%) for TARE after 4 weeks. After 3 and 6 months, hypertrophy converged without a statistically significant difference, with a volume gain of 103% (IQR: 86%–119%) for PVE versus 82% (IQR: 70%–96%) for TARE after 3 months and 115% (IQR: 70%–46%) for PVE versus 86% (IQR: 58%–111%) for TARE after 6 months. A strong correlation was observed between radiation dose (median 162 Gy, IQR: 139–175) and hypertrophy.ConclusionsPVE resulted in rapid hypertrophy within 1 month of the procedure, followed by a plateau, whereas TARE resulted in comparable hypertrophy by 3–6 months. TARE-induced hypertrophy correlated with radiation absorbed dose. 相似文献
5.
6.
7.
Humburg Dennis Timpe Maximilian Wranze-Bielefeld Erich Martens Florian Rupp Dennis Sassen Martin C. 《Notfall & Rettungsmedizin》2022,25(8):578-584
Notfall + Rettungsmedizin - Es wird über die präklinische Versorgung eines 82-jährigen Patienten im septischen Schock bei akuter Pankreatitis berichtet. Initial wurde nur ein... 相似文献
8.
9.
10.
Carolin
Herrmann Maximilian Pilz Meinhard Kieser Geraldine Rauch 《Statistics in medicine》2020,39(15):2067-2100
In standard clinical trial designs, the required sample size is fixed in the planning stage based on initial parameter assumptions. It is intuitive that the correct choice of the sample size is of major importance for an ethical justification of the trial. The required parameter assumptions should be based on previously published results from the literature. In clinical practice, however, historical data often do not exist or show highly variable results. Adaptive group sequential designs allow a sample size recalculation after a planned unblinded interim analysis in order to adjust the sample size during the ongoing trial. So far, there exist no unique standards to assess the performance of sample size recalculation rules. Single performance criteria commonly reported are given by the power and the average sample size; the variability of the recalculated sample size and the conditional power distribution are usually ignored. Therefore, the need for an adequate performance score combining these relevant performance criteria is evident. To judge the performance of an adaptive design, there exist two possible perspectives, which might also be combined: Either the global performance of the design can be addressed, which averages over all possible interim results, or the conditional performance is addressed, which focuses on the remaining performance conditional on a specific interim result. In this work, we give a compact overview of sample size recalculation rules and performance measures. Moreover, we propose a new conditional performance score and apply it to various standard recalculation rules by means of Monte-Carlo simulations. 相似文献